株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

主要先進国市場における大鬱病性障害(MDD)治療薬市場:新製品の発売と新たな補助療法への謙虚な取り組みが特許失効を埋め合わせる

Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries

発行 GBI Research 商品コード 318231
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
主要先進国市場における大鬱病性障害(MDD)治療薬市場:新製品の発売と新たな補助療法への謙虚な取り組みが特許失効を埋め合わせる Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries
出版日: 2014年10月31日 ページ情報: 英文 70 Pages
概要

主要先進国市場における大鬱病性障害(MDD)治療薬市場は、2013年の87億米ドルから、2020年には81億米ドル規模まで、CAGRで1.1%のマイナス成長が予測されています。

当レポートでは、主要先進国市場における大鬱病性障害(MDD)治療薬市場について調査分析し、市場の概要、上市製品、パイプライン製品、市場予測、取引と戦略的統合などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 病因
  • 病態生理学
  • 診断
  • 分類
  • 疫学
  • 予後
  • 治療と管理

第3章 上市製品

  • 治療状況
  • 有効性と安全性の比較

第4章 パイプライン製品

  • パイプライン全体
  • パイプライン分析:分子タイプ別
  • パイプライン分析:作用機序別
  • 臨床試験
  • パイプラインにおける有望薬の候補
    • IOPC-34712 (brexpiprazole)
    • ALKS-5461
    • Amitifadine (EB-1010)

第5章 市場予測

  • 地域別市場
    • 世界市場
    • 北米
    • 欧州主要5ヶ国
    • 日本
  • 促進要因と障壁
    • 促進要因
    • 障壁

第6章 取引と戦略的統合

  • 主なライセンス取引
  • 主な共同開発取引

第7章 付録

図表

目次
Product Code: GBIHC342MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries", which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of the pipeline, clinical trial failure rate and deal analysis for MDD. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts. In 2013, the value of the MDD therapeutics market in major developed countries amounted to an estimated $8.7 billion. The market is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.1% between 2013 and 2020 to reach $8.1 billion. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period.

Scope

The report analyzes treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals MDD in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.The report includes -

  • A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms.
  • In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type.
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
  • Discussion of the drivers and barriers for market growth.
  • In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006.

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

  • Understand the MDD pipeline and the factors that indicate that it is becoming more innovative. Observe detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be.
  • Follow the trends in MDD clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for MDD therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
  • Observe the potential growth patterns expected for the MDD market over the forecast period. Identify which countries are expected to contribute the most to this growth and devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the MDD market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Etiology
  • 2.2. Pathophysiology
  • 2.3. Diagnosis
  • 2.4. Classification
  • 2.5. Epidemiology
  • 2.6. Prognosis
  • 2.7. Treatment and Management
    • 2.7.1. Antidepressants

3. Marketed Products

  • 3.1. Therapeutic Landscape
    • 3.1.1. Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories
    • 3.1.2. Viibryd (vilazodone) - Forest (Actavis)
    • 3.1.3. Cymbalta (duloxetine) - Eli Lilly
    • 3.1.4. Pristiq (desvenlafaxine) - Pfizer
    • 3.1.5. Seroquel XR (quetiapine) - AstraZeneca
    • 3.1.6. Brintellix (vortioxetine) - Takeda and Lundbeck
    • 3.1.7. Abilify (aripiprazole) - Otsuka
  • 3.2. Comparative Efficacy and Safety

4. Major Depressive Disorder Market to 2020 - Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Patient Enrollment and Clinical Trial Size
    • 4.4.3. Duration
  • 4.5. Promising Drug Candidates in the Pipeline
    • 4.5.1. OPC-34712 (brexpiprazole) - Otsuka and Lundbeck
    • 4.5.2. ALKS-5461 - Alkermes
    • 4.5.3. Amitifadine (EB-1010) - Euthymics Bioscience

5. Market Forecast to 2020

  • 5.1. Geographical Markets
    • 5.1.1. Global Market
    • 5.1.2. North America
    • 5.1.3. Top Five European Countries
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Licensing Deals
    • 6.1.1. Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets
    • 6.1.2. Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd
    • 6.1.3. AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept
    • 6.1.4. Impax Labs Enters into Licensing Agreement with Wyeth
  • 6.2. Major Co-development Deals
    • 6.2.1. Lundbeck Enters into Co-Development Agreement with Otsuka Pharma
    • 6.2.2. Azaya Lundbeck Enters into Co-Development Agreement with Takeda

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Pre-registration
    • 7.1.7. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. UK
    • 7.2.4. France
    • 7.2.5. Germany
    • 7.2.6. Italy
    • 7.2.7. Spain
    • 7.2.8. Japan
    • 7.2.9. Canada
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Major Depressive Disorder Market, Global, Symptoms and Associated Features, 2008
  • Table 2: Major Depressive Disorder Market, Global, Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10), 2013
  • Table 3: Major Depressive Disorder Market, Global, Prevalence (%), 2011
  • Table 4: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Discovery), 2013
  • Table 5: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
  • Table 6: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase I), 2013
  • Table 7: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase II), 2013
  • Table 8: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase III), 2013
  • Table 9: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013
  • Table 10: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
  • Table 11: Major Depressive Disorder Market, Global, Forecast Data, 2013-2020
  • Table 12: Major Depressive Disorder Market, US, Forecast Data, 2013-2020
  • Table 13: Major Depressive Disorder Market, UK, Forecast Data, 2013-2020
  • Table 14: Major Depressive Disorder Market, France, Forecast Data, 2013-2020
  • Table 15: Major Depressive Disorder Market, Germany, Forecast Data, 2013-2020
  • Table 16: Major Depressive Disorder Market, Italy, Forecast Data, 2013-2020
  • Table 17: Major Depressive Disorder Market, Spain, Forecast Data, 2013-2020
  • Table 18: Major Depressive Disorder Market, Japan, Forecast Data, 2013-2020
  • Table 19: Major Depressive Disorder Market, Canada, Forecast Data, 2013-2020

List of Figures

  • Figure 1: Major Depressive Disorder Market, Global, Pathology, 2010
  • Figure 2: Major Depressive Disorder Market, Global, Stages of Major Depressive Disorder and Respective Treatment Approach, 2010
  • Figure 3: Major Depressive Disorder Market, Global, Treatment Phases, 2010
  • Figure 4: Major Depressive Disorder Market, Global, Lexapro (escitalopram) Annual Sales ($bn), 2006-2013
  • Figure 5: Major Depressive Disorder Market, Global, Viibryd (vilazodone) Annual Sales ($m), 2011-2013
  • Figure 6: Major Depressive Disorder Market, Global, Cymbalta (duloxetine) Annual Sales ($bn), 2005-2013
  • Figure 7: Major Depressive Disorder Market, Global, Pristiq (desvenlafaxine) Annual Sales ($m), 2009-2013
  • Figure 8: Major Depressive Disorder Market, Global, Seroquel XR (quetiapine) Annual Sales ($bn), 2008-2013
  • Figure 9: Major Depressive Disorder Market, Global, Abilify (aripiprazole) Annual Sales ($bn), 2005-2013
  • Figure 10: Major Depressive Disorder Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap, 2013
  • Figure 11: Major Depressive Disorder Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013
  • Figure 12: Major Depressive Disorder Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 13: Major Depressive Disorder Market, Global, Pipeline by Mechanism of Action, 2013
  • Figure 14: Major Depressive Disorder Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2013
  • Figure 15: Major Depressive Disorder Market, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 16: Major Depressive Disorder Market, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2013
  • Figure 17: Major Depressive Disorder Market, Global, Clinical Trial Size (Participants), 2013
  • Figure 18: Major Depressive Disorder Market, Global, Pipeline Clinical Trial Duration (months), 2013
  • Figure 19: Major Depressive Disorder Market, Global, Treatment Use Patterns and Market Size, 2013-2020
  • Figure 20: Major Depressive Disorder Market, US and Canada, Treatment Use Patterns (million), 2013-2020
  • Figure 21: Major Depressive Disorder Market, US and Canada, Annual Cost of Therapy ($), 2013-2020
  • Figure 22: Major Depressive Disorder Market, US and Canada, Market Size, 2013-2020
  • Figure 23: Major Depressive Disorder Market, Top Five European Markets, Treatment Use Patterns (million), 2013-2020
  • Figure 24: Major Depressive Disorder Market, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
  • Figure 25: Major Depressive Disorder Market, Top Five European Markets, Market Size ($m), 2013-2020
  • Figure 26: Major Depressive Disorder Market, Japan, Treatment Use Patterns (million), 2013-2020
  • Figure 27: Major Depressive Disorder Market, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 28: Major Depressive Disorder Market, Japan, Market Size ($m), 2013-2020
  • Figure 29: Major Depressive Disorder Market, Global, Deals by Value, Year and Stage of Development, 2006-2013
  • Figure 30: Major Depressive Disorder Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2013
  • Figure 31: Major Depressive Disorder Market, Global, Licensing Deals by Geography, 2006-2013
  • Figure 32: Major Depressive Disorder Market, Global, Co-development Deals by Geography, 2006-2013
  • Figure 33: GBI Research Market Forecasting Model (Example)
Back to Top